Emendo Biotherapeutics

Rachel Diamant, Chief Intellectual Property Officer and Head of Pipeline Development

Oct. 12 | 10:45am | BlueRock Therapeutics Ballroom

Miami, FL

In-person Presentation
EmendoBio is a pioneering, next-generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, EmendoBio’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our dual OMNI™ technology platforms enable us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered incurable.

By using this website you agree to accept our Privacy Policy and Terms & Conditions